, Volume 58, Issue 11, pp 3068-3069
Date: 08 Aug 2013

Is It Time to Take a Pass on the Increased Number of Passes in EUS-FNA?

This is an excerpt from the content

Despite the extensive use of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), there still exists a wide variation in the number of samples required to ensure acquisition of diagnostic material from pancreatic lesions. Although multiple passes can be performed during EUS-FNA, prolonging the procedure likely increases risk, decreases procedural efficiency, and increases the probability of samples being tainted with blood. It has been 21 years since EUS-FNA was used to obtain pancreatic tissue for cytologic analysis [1, 2], 16 years since the publication of the first reports evaluating the clinical impact and staging of pancreatic lesions sampled by EUS-FNA [3], and 14 years since the publication of the initial reports of the evaluation of the number of passes needed to obtain a diagnostic yield and the significance of on-site cytopathology during the procedure [47]. During this time, the focus has been on determining the necessity of on-site cytopathologic evaluation, the